Starry Pharmaceutical Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 1,905

Employees

  • Stock Symbol
  • 603520

Stock Symbol

  • Investments
  • 7

  • Share Price
  • $1.16
  • (As of Monday Closing)

Starry Pharmaceutical General Information

Description

Zhejiang Starry Pharmaceutical Co Ltd is engaged in R&D, manufacture and marketing of active ingredient and intermediate X-CT non-ionic contrast agent series and Fluoroquinolones series.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • No. 1 Starry Road of Modern Industrial Centralization Zone
  • Xianju County
  • Taizhou, Zhejiang 317306
  • China
+86 800
Primary Industry
Pharmaceuticals
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • No. 1 Starry Road of Modern Industrial Centralization Zone
  • Xianju County
  • Taizhou, Zhejiang 317306
  • China
+86 800

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Starry Pharmaceutical Stock Performance

As of 16-Nov-2026, Starry Pharmaceutical’s stock price is $1.16. Its current market cap is $509M with 438M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.16 $1.16 $1.14 - $2.11 $509M 438M 6.52M

Starry Pharmaceutical Financials Summary

As of 30-Sep-2026, Starry Pharmaceutical has a trailing 12-month revenue of $379M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 955,725 917,821 782,252 1,018,275
Revenue 378,521 340,100 327,536 310,392
EBITDA 15,022 45,011 35,225 45,225
Net Income 3,857 1,422 (6,843) 6,252
Total Assets 870,819 879,734 828,155 778,210
Total Debt 415,207 412,539 351,275 431,174
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Starry Pharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Starry Pharmaceutical‘s full profile, request access.

Request a free trial

Starry Pharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Starry Pharmaceutical Investments & Acquisitions (7)

Starry Pharmaceutical’s most recent deal was a Secondary Transaction - Private with Ruishi Pharmaceutical for . The deal was made on 07-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ruishi Pharmaceutical 07-Sep-2026 Secondary Transaction - Private Other Healthcare Services
DDSome Lab 06-Jul-2023 Later Stage VC Drug Delivery
Eyougene 17-Feb-2021 Corporate Drug Discovery
DDSome Lab 01-Jan-2021 Later Stage VC Drug Delivery
Haishen Pharmaceutical 01-Oct-2019 Secondary Transaction - Private Pharmaceuticals
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Starry Pharmaceutical ESG

Risk Overview

Risk Rating

Updated June, 30, 2023

35.26 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,201

Rank

Percentile

Pharmaceuticals

Industry

of 863

Rank

Percentile

Pharmaceuticals

Subindustry

of 430

Rank

Percentile

To view Starry Pharmaceutical’s complete esg history, request access »

Starry Pharmaceutical Exits (2)

Starry Pharmaceutical’s most recent exit was on 06-Jul-2023 from DDSome Lab. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
DDSome Lab 06-Jul-2023 Completed
  • 2 buyers
DDSome Lab 01-Jan-2021 Later Stage VC Completed
  • 3 buyers
To view Starry Pharmaceutical’s complete exits history, request access »

Starry Pharmaceutical Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
iMAX Diagnostic Imaging Cork, Ireland 2011
Haishen Pharmaceutical Taizhou, China 2003

Starry Pharmaceutical FAQs

  • When was Starry Pharmaceutical founded?

    Starry Pharmaceutical was founded in 1997.

  • Where is Starry Pharmaceutical headquartered?

    Starry Pharmaceutical is headquartered in Taizhou, China.

  • What is the size of Starry Pharmaceutical?

    Starry Pharmaceutical has 1,905 total employees.

  • What industry is Starry Pharmaceutical in?

    Starry Pharmaceutical’s primary industry is Pharmaceuticals.

  • Is Starry Pharmaceutical a private or public company?

    Starry Pharmaceutical is a Public company.

  • What is Starry Pharmaceutical’s stock symbol?

    The ticker symbol for Starry Pharmaceutical is 603520.

  • What is the current stock price of Starry Pharmaceutical?

    As of 16-Nov-2026 the stock price of Starry Pharmaceutical is $1.16.

  • What is the current market cap of Starry Pharmaceutical?

    The current market capitalization of Starry Pharmaceutical is $509M.

  • What is Starry Pharmaceutical’s current revenue?

    The trailing twelve month revenue for Starry Pharmaceutical is $379M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process